An interventional study of E967-Xylitol and E968-Erythritol in Obesity, sponsored by University Hospital, Basel, Switzerland. Completed at 3 sites in 3 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-07-20.
Sponsored by University Hospital, Basel, Switzerland · Not applicable, Interventional, and Basic science
Sugar alcohols such as xylitol and erythritol are increasingly popular as sugar substitutes in the food industry and are also recommended to diabetic patients. Both substances are already in use in the food industry and are freely available. Since the 1970s, beneficial effects on oral health could be demonstrated as oral bacteria were influenced positively. Animal studies showed an increase in gut Clostridium perfringens after xylitol intake; certainly a non-desirable effect. However, studies on effects of erythritol and xylitol on the human gut microbiota are lacking so far. In this trial, investigators aim to examine whether gut microbiota and glucose tolerance can be influenced by polyol intake in a non-diabetic but obese cohort.
6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.
This study's enrollment of 64 is below the median of 78 across 4,878 interventional studies indexed under Obesity.
Browse Obesity studies →University Hospital, Basel, Switzerland is the lead sponsor of 968 studies on the registry; 191 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
20 obese, non-diabetic candidates will serve as control-group. All assessments are carried out just as in the intervention groups.
20 obese, non-diabetic candidates will receive a daily dose of 24g of xylitol.
Dietary Supplement: E967-Xylitol
20 obese, non-diabetic candidates will receive a daily dose of 36g of erythritol.
Dietary Supplement: E968-Erythritol
Also known as: Xylitol
Also known as: Erythritol
Glucose tolerance measured with oral glucose tolerance test
Time frame: change from baseline to 8 weeks after polyol intake
Human gut microbiota composition measured with metagenomic shotgun sequencing
Time frame: change from baseline to 8 weeks after polyol intake
Gut microbial-related metabolites in feces
Metabolomic analysis of the bacterial metabolites present in the feces by combining nuclear magnetic resonance (1H-NMR) and mass spectrometry
Time frame: change from baseline to 8 weeks after polyol intake
Gastrointestinal tolerance assessed by questionnaire
Gastrointestinal Symptoms Rating Scale (Svedlund et al)
Time frame: change from baseline to 8 weeks after polyol intake
Gut microbial-related metabolites in urine
Metabolomic analysis of the bacterial metabolites present in the urine by combining nuclear magnetic resonance (1H-NMR) and mass spectrometry
Time frame: change from baseline to 8 weeks after polyol intake
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Basel, Switzerland